On August 31, 2023, ProMIS Neurosciences, Inc., closed the transaction. The company issued 9,945,969 common share at a price of $1.88 per unit consisting of one common share and one warrant and 954,725 pre-funded units at a price of $1.87 per unit consisting of one pre-funded warrant for the gross proceeds of $20.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | -5.66% | -4.04% | +30.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.43% | 28.44M | |
+16.45% | 122B | |
+21.96% | 116B | |
+25.44% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.03% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- PMN Stock
- News ProMIS Neurosciences, Inc.
- ProMIS Neurosciences, Inc. announced that it has received $20.483758 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc.